SGX queries Biolidics on A*Star licence deal
Add BT as a preferred sourceClaudia Tan HS
Singapore
THE Singapore Exchange (SGX) on Wednesday posed a series of queries to Biolidics about the details of a licence agreement the Catalist-listed firm had inked as well as the timing of its trading halt and announcement.
In a filing late Tuesday night, Biolidics said it had on July 9 entered into a five-year licence agreement with Accelerate Technologies, the commercialisation arm of the Agency for Science, Technology and Research (A*Star), to use the agency's technology for the detection of Covid-19 viral spike/Angiotensin-Converting Enzyme 2 (ACE2) blocking antibodies.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
From post-war hardships to ‘era of national rise’: Vietnam’s family firms face first succession test
‘We’re not a bubble tea brand’: Chagee aims to double Asia-Pacific footprint to 600 stores by 2027
